WntResearch : Presentation of the ad hoc observations in the phase 2 study NeoFox

Presentation of ad hoc observations in NeoFox

Pernilla Sandwall, CEO

10 January 2023

Disclaimer

This Presentation (the "Presentation"), which is personal to the recipient, is issued by WntResearch AB (the "Company"). The Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. The Presentation may not be reproduced, redistributed, passed on or published, in whole or

in part, to any other person for any purpose. Unless otherwise stated, the Company is the source for all data contained in the Presentation. Such data is provided as at the date of this Presentation and is subject to change without notice. The Presentation (together with any further information which may be provided to the addressee) is made available on the condition that it is for use only by the addressee specified above for the sole purpose of evaluating the Company and shall not be passed on to any other person or copied or reproduced, copied, distributed, disclosed or published in whole or part and shall be immediately returned along with any other copies or destroyed at any time at the request of Company.

The Presentation is solely for your information and should not be relied upon and shall not confer rights or remedies upon, you or any of your employees, creditors, holders of securities or other equity holders or any other person. No representation or warranty, express or implied, is made by the Company or any of its directors, officers, employees, representatives, advisers or agents or any other person or entity as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever its source, contained in this document (including any written or oral information made available to any interested party in connection thereto), and no liability whatsoever is accepted by any such person in relation to any such information or opinion. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its credit worthiness and does not purport to be all-inclusive or to contain all information that prospective investors may desire or that may be required to properly evaluate the business, prospects or value of the Company.

The information in this Presentation has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. The Company or any of their respective subsidiaries or affiliates or any of such person's directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this Presentation or otherwise arising in connection therewith. The Company is under no obligation to submit further information. By receiving this Presentation and/or attending a presentation concerning the contents hereof you acknowledge that you will be solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company.

This Presentation includes forward-looking statements. All statements other than statements of historical fact included in this Presentation, including, without limitation, those regarding

the Company's financial position, business strategy, management plans and objectives for future operations are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this Presentation and Vator Securities and the Company expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Company Presentation as a result of any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.

Introduction to Foxy-5

Unique clinical stage Foxy-5 peptide in Phase 2 with potential to prevent the spread of cancer in patients with colon cancer

High unmet need in stage II and III colon cancer with a significant commercial opportunity: Targeting 65,000 patients with USD > 500 million in revenue1

Foxy-5 based on Professor Tommy Andersson, founder's research discoveries in the area of WNT5A

Experienced organization with competencies in drug development, business development, and commercialization

Additional value creation is possible with Foxy-5 in additional cancer types

1) GlobalData, Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028; GLOBOCAN 2018; Global Cancer Observatory. Lyon, France: International Agency for Research on Cancer

Observations made in the ongoing NeoFox phase 2 study

ctDNA values analysed from preliminary diagnosis to the end of the study; FU up to 24 months after surgery

Foxy-5 treatment

(versus control arm = Standard of Care)

		Minimum 9 treatments				Max 39 doses (in total) or
		pre-surgery (3 weeks)				start of adjuvant
						treatment

Preliminary	Surgery
Diagnosis	Removal of primary tumour

Follow up

Adjuvant therapy

OS/DFS/RFI/ctDNA

at 24 months

Staging based on CT

Staging based on pathology

Primary efficacy read-outs

Observations made at surgery after minimum three weeks treatment prior to surgery

Could neo-adjuvant treatment with Foxy-5 have an effect on the tumour burden?

More Foxy-5 treated patients has TNM downstaging compared to control

Comparing TNM staging at randomization (based on clinical staging) to TNM staging at surgery (surgical staging)

% patients

70

64%

60

50

42%

40

35%

31%

30

					24%
20
10
		23	5%
35			17	19
3	13
0
Downstaging	No change	Upstaging
			Foxy-5 (n= 55)		Control (n=55)

Foxy-5 treatment results in TNM downstaging

52% more Foxy-5 patients achieves TNM downstaging

Foxy-5 treatment is significantly associated with more TNM downstaging compared to control (p=0.012)

The TNM stage of a cancer describes how much cancer is in the body

TNM: T describes the extent (size) of the tumour and how far it has grown into the wall of the colon; N describes spread of cancer to nearby lymph nodes; and M describes metastasis (spread of cancer to other parts of the body).

For the purpose of the analyses:

• The same TNM staging at randomization and surgery = Unchanged
• Less TNM staging at surgery compared to randomization = Downstaging
• Higher TNM staging at surgery compared to randomization = Upstaging